After the Results: Evolving GVHD Prophylaxis Strategies for HLA-mismatched HCT
January 12, 2021
Description
Getting more patients to successful transplantation is laced with obstacles such as age, ethnicity, and timing. In this recorded webinar, you will learn about recent research by the CIBMTR® (Center for International Blood and Marrow Transplant Research®) presented at the 2020 ASH Annual Meeting, to provide participants with data, summaries and strategies through an exploration of alternative graft sources and impacts on current practices.
Working towards inclusivity and expanding access to older and underserved, ethnically diverse patients, these recent studies show promising improvements in patient outcomes.
Learning Objectives
Our expert panelists discuss:
- Impact of HLA mismatching on unrelated donor HCT
- Role of MMUD among alternative (HLA-mismatched) graft sources
- Novel approaches to HCT that show promise for use of HLA mismatched donors
- Initiatives developed by the NMDP to facilitate transplant across HLA barriers
Speakers
- Stephen Spellman, MSB, Vice President, Research, NMDP, Senior Scientific Director, Immunobiology Research Program, CIBMTR®
- Steven Devine, MD, Chief Medical Officer, NMDP, Associate Scientific Director, CIBMTR®
- Bronwen Shaw, MD, PhD, Scientific Director, CIBMTR®, Professor of Medicine, Froedtert, Medical College of Wisconsin
- Monzr Al-Malki, MD, Associate Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
- Asad Bashey, MD, PhD, Clinical Research Medical Director, The Blood and Marrow Transplant Program, Northside Hospital
- Filippo Milano, MD, PhD, Associate Professor, Director, Cord Blood Transplantation Program, Clinical Research Division, Fred Hutchinson Cancer Research Center
Target Audience
Hematology, oncology and BMT physicians, nurses; hematology, oncology and BMT clinical operation partners, transplant center physicians, nurses, and coordinators, and advanced level case managers and health professionals.